{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"154.2","value":"37200"},{"comment":"NA: Geo-CV could not be calculated for 1 participant.","groupId":"OG001","spread":"NA","value":"2690"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"CR/CRi"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.4","value":"31700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"NR"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"132.5","value":"67700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"148.8","value":"39200"},{"comment":"NA: Geo-CV could not be calculated for 1 participant.","groupId":"OG001","spread":"NA","value":"2690"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"All Participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Cmax is the maximum (peak) observed in peripheral blood drug concentration after single dose administration reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas M60 is the actual timepoint for endpoint assessment. The reported Cmax is the summary of maximum level observed based on the data from each patient and based on all the data that's been collected for up to 60 months in a patient.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PAS: The PAS consisted of patients in the FAS who had at least one sample providing evaluable cellular kinetic data for tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Pharmacokinetics (PK) Parameter: Cmax by qPCR in Peripheral Blood, by Day 28 Disease Response by IRC","type":"SECONDARY","unitOfMeasure":"copies/ug"}